期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

应用组织芯片研究星形细胞瘤组织中Fas及TOPO-Ⅱα的表达及意义

Expression and significance of Fas and TOPO-Ⅱα in astrocytoma analysed by tissue microarray
下载PDF
导出
摘要 目的研究Fas及TOPO-Ⅱα在星形细胞瘤组织中的表达,探讨其与星形细胞瘤发生发展的关系。方法应用组织芯片技术,S-P免疫组织化学方法检测56例不同级别的星形细胞瘤及10例正常脑组织中两种蛋白的表达情况。结果Fas、TOPO-Ⅱα的蛋白在各级星形细胞瘤中总的表达率分别为62.8%和60.7%,二者的表达与星形细胞瘤的病理分级呈正相关。星形细胞瘤中Fas与TOPO-Ⅱα蛋白表达呈显著的正相关。结论脑星形细胞瘤中Fas与TOPO-Ⅱα蛋白表达与肿瘤病理类型及恶性程度密切相关。 Objective To investigate the expression of Fas and TOPO-Ⅱα in astrocytoma and study their relation to histogenesis and development of astrocytoma. Methods Using S-P immunohistochemical method to investigate the expression of Fas and TOPO-Ⅱα in 56 astrocytomas and 10 normal brain tissues on tissue microarray sections. Results Expression of Fas and TOPO-Ⅱα( in astrocytoma of all grades was 62.5% and 60.7% respectively, both of them were positively related to malignant grading of astrocytomas. The expression of Fas is positively related to the expression of TOPO-Ⅱα. Conclusion Expression of Fas and TOPO-Ⅱα is related to histopathological type and degree of malignancy astrocytomas.
作者 刘青华 李灵敏 王晋芬
机构地区 山西医科大学病理教研室 山西省肿瘤医院病理科
出处 《山西医科大学学报》 CAS 2005年第3期299-301,共3页 Journal of Shanxi Medical University
关键词 星形细胞瘤 抗原 CD95 抗原 TOPO-Ⅱα 寡核苷酸序列分析 免疫组织化学 astrocytoma antigen,CD95 antigen,TOPO-Ⅱα oligonucleotide array sequence analysis immunohistochemistry
分类号 R739.41 [医药卫生—肿瘤]
  • 相关文献

参考文献7

  • 1张建中,黄英武,刘冬梅,杨利桃,韩瑞刚,王晋芬,岳茂兴.组织芯片技术的建立及其在大肠癌的研究[J].世界华人消化杂志,2002,10(2):157-160. 被引量：27
  • 2Friedrichs K,Gluba S, Eidtmann H, et al. Overexpression of p53and prognosis in breast cancer[J ]. Cancer, 1993,72(12) :3641.
  • 3Nagata S,Golstein P. The Fas death factor[J].Science,1995,267(5203): 1449～1456.
  • 4Pamey IF,Hao KC. Glioma immunology and immunotherapy[J].Neurosurgery, 2000,460(4): 778～ 791.
  • 5Tachibana O, Nakazawa H, Lampe J, et al. Expression of Fas/Apo -1 duing the progression of astrocytomas[J ]. Cancer Research,1995,55(23) :5528～5530.
  • 6郑宇,浦佩玉,王春燕.人脑胶质瘤中Fas及FasL的表达[J].中国神经精神疾病杂志,2002,28(3):179-181. 被引量：2
  • 7Schneider P, Holler N, Bodner JL, et al. Conversion of membranebound Fasligend to its soluble form is associated with down regulation of its proactivity and loss of liver toxicity[J ]. Exp Med, 1998,187(8): 1205.

二级参考文献48

  • 1彭琼,浦佩玉,王春艳,刘增辉,王欣,王瑞琳.脑肿瘤中P53蛋白的表达及Ki－67LI的相关性研究[J].中华神经外科杂志,1996,12(2):79-83. 被引量：15
  • 2Kallioniemi OP, Wagner U, Kononen J, Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genetics 2001; 10:657-662
  • 3Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P,Leighton S, Torhors J, Mihatsch MJ, Sauter G, Kalioniemi OP.Tissue microarray for high-throughput molecular profiling of tumor specimens. Nature Med 1998; 4:844-847
  • 4Moch H, Kononen T, Kallioniemi OP, Sauter G. Tissue microarray: what will they bring to molecular and anatomic pathology? Adv Anat Pathol 2001 ;8:14-20
  • 5Rimm DL, Camp RL, Charette LA, Costa J, Olsen DA, Reiss M.Tissue microarray: a new technology for amplification of tissue resources. CancerJ 2001 ;7:24-31
  • 6Nagle RB. New molecular approaches to tissue analysis. J Histochem Cytochem 2001 ;49:1063-1064
  • 7Bubendorf L, Nocito A, Moch H, Sauter G. Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol 2001; 195: 72-79
  • 8Yang GP, Ross DT, Kuang WW, Brown PO, Weigel RJ. Combining SSH and cDNA microarrays for rapid identification of differentially expressed genes. Nucleic Acids Res 1999 ;27:1517-1523
  • 9Wang K, Gan L, Jeffery E, Gayle M, Gown AM, Skelly M, Nelson PS, Ng WV, Schummer M, Hood L, Mulligan J. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene 1999;229:101-108
  • 10Khan J, Saal LH, Bittner ML, Chen Y, Trent JM, Meltzer PS.Expression profiling in cancer using eDNA microarrays. Electrophoresis1999; 20: 223-229

共引文献27

山西医科大学学报
2005年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部